Patents by Inventor Zbigniew Dominski

Zbigniew Dominski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotides which combat aberrant splicing and methods of using the same
    Patent number: 5976879
    Abstract: A method of combatting aberrant splicing in a pre-mRNA molecule containing a mutation is disclosed. When present in the pre-mRNA, the mutation causes the pre-mRNA to splice incorrectly and produce an aberrant mRNA or mRNA fragment different from the mRNA ordinarily encoded by the pre-mRNA. The method comprises hybridizing an antisense oligonucleotide to the pre-mRNA molecule to create a duplex molecule under conditions which permit splicing. The antisense oligonucleotide is one which does not activate RNase H, and is selected to block a member of the aberrant set of splice elements created by the mutation so that the native intron is removed by splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for carrying out the method are also disclosed.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: November 2, 1999
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ryszard Kole, Zbigniew Dominski
  • Antisense oligonucleotides which combat aberrant splicing and methods of using the same
    Patent number: 5916808
    Abstract: A method of combatting aberrant splicing in a pre-mRNA molecule containing a mutation is disclosed. When present in the pre-mRNA, the mutation causes the pre-mRNA to splice incorrectly and produce an aberrant mRNA or mRNA fragment different from the mRNA ordinarily encoded by the pre-mRNA. The method comprises hybridizing an antisense oligonucleotide to the pre-mRNA molecule to create a duplex molecule under conditions which permit splicing. The antisense oligonucleotide is one which does not activate RNase H, and is selected to block a member of the aberrant set of splice elements created by the mutation so that the native intron is removed by splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for carrying out the method are also disclosed.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: June 29, 1999
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ryszard Kole, Zbigniew Dominski
  • Antisense oligonucleotides which combat aberrant splicing and methods of using the same
    Patent number: 5665593
    Abstract: A method of combatting aberrant splicing in a pre-mRNA molecule containing a mutation is disclosed. When present in the pre-mRNA, the mutation causes the pre-mRNA to splice incorrectly and produce an aberrant mRNA or mRNA fragment different from the mRNA ordinarily encoded by the pre-mRNA. The method comprises hybridizing an antisense oligonucleotide to the pre-mRNA molecule to create a duplex molecule under conditions which permit splicing. The antisense oligonucleotide is one which does not activate RNase H, and is selected to block a member of the aberrant set of splice elements created by the mutation so that the native intron is removed by splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for carrying out the method are also disclosed.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: September 9, 1997
    Assignee: University of North Carolina
    Inventors: Ryszard Kole, Zbigniew Dominski
  • Antisense oligonucleotides which combat aberrant splicing and methods of using the same
    Patent number: 5627274
    Abstract: A method of combatting aberrant splicing in a pre-mRNA molecule containing a mutation is disclosed. When present in the pre-mRNA, the mutation causes the pre-mRNA to splice incorrectly and produce an aberrant mRNA or mRNA fragment different from the mRNA ordinarily encoded by the pre-mRNA. The method comprises hybridizing an antisense oligonucleotide to the pre-mRNA molecule to create a duplex molecule under conditions which permit splicing. The antisense oligonucleotide is one which does not activate RNase H, and is selected to block a member of the aberrant set of splice elements created by the mutation so that the native intron is removed by splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for carrying out the method are also disclosed.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: May 6, 1997
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ryszard Kole, Zbigniew Dominski